Company news

Lipocine Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Lipocine Announces USPTO Declaration Of Interference Between Lipocine And Clarus Patent Applications

January 13, 2021

Lipocine Announces Positive Topline Phase 2 Results from LPCN 1144 Ongoing LiFT Study in Biopsy-Confirmed NASH Subjects

January 11, 2021

Lipocine Announces Open Label Extension to Ongoing LPCN 1144 LiFT Study

December 29, 2020

Lipocine Announces Update on Jury Trial in Patent Infringement Lawsuit Against Clarus Therapeutics

December 28, 2020

Lipocine Announces Tentative Approval of TLANDO™

December 7, 2020

Lipocine Announces Deletion of Unauthorized Changes to Company's Website

December 7, 2020

Lipocine Provides New Regulatory Update on TLANDO™

December 3, 2020

Lipocine Announces Third Quarter 2020 Financial and Operational Results

November 9, 2020

Lipocine Provides Regulatory Update on TLANDO™

November 5, 2020

Lipocine Announces Presentations at the 21st Annual Fall Meeting of the Sexual Medicine Society of North America

October 13, 2020

Lipocine Announces Completion of Enrollment in the LPCN 1144 LiFT Study

September 20, 2020

Lipocine Provides Regulatory Update for TLANDO™

August 27, 2020

Lipocine Announces Second Quarter 2020 Financial and Operational Results

August 5, 2020

Lipocine Announces Publication of LPCN 1144 Liver Fat Study ("LFS") Results

August 2, 2020

Lipocine Announces Derivative Suit Was Dismissed

July 30, 2020

Lipocine Regains Complinace With Nasdaq Minimum Bid Price Requirement

July 12, 2020

Lipocine Announces Presentations on TLANDO™ at AUA Virtual Experience 2020

May 14, 2020

Lipocine Announces First Quarter 2020 Financial and Operational Results

May 6, 2020

FDA Clears LPCN 1148 IND Application for Phase 2 Cirrhosis Trial

May 4, 2020

Lipocine Announces US Court of Appeals for the Federal Circuit Affirms Decision of USPTO

April 8, 2020

Lipocine Announces Outcome of Markman Hearing in Patent Infringement Suit Against Clarus

March 25, 2020

Lipocine Announces 2019 Year End Financial and Operational Results

March 12, 2020

Lipocine Announces TLANDO™ PDUFA Date of August 28, 2020

March 3, 2020

Lipocine Announces Closing Of Registered Direct Offering Of Common Stock And Warrants

February 26, 2020

Lipocine Announces $6 Million Registered Direct Offering Priced At-The-Market

February 24, 2020

Lipocine Announces Regulatory Path Forward for TLANDO™ Resubmission

February 23, 2020

Lipocine Announces Closing Of Public Offering Of Common Stock And Warrants

November 17, 2019

Lipocine Announces Pricing Of Public Offering Of Common Stock And Warrants

November 13, 2019

Lipocine Announces Launch Of Public Offering Of Common Stock And Warrants

November 12, 2019

Lipocine Announces Third Quarter 2019 Financial and Operational Results

November 11, 2019

Lipocine Receives Complete Response Letter for TLANDO(TM) from U.S. FDA

November 10, 2019

Lipocine To Present LPCN 1144 Poster Of Distinction At The Liver Meeting® 2019

September 30, 2019

First Biopsy Confirmed Nash Patient Dosed In Lipocine LiFT Study Of LPCN 1144

September 29, 2019

Lipocine Announces Presentations at the 20th Annual Fall Meeting of the Sexual Medicine Society of North America

September 22, 2019

Lipocine Announces Second Quarter 2019 Financial and Operational Results

August 6, 2019

Lipocine Receives FDA Clearance for Clinical Testing its NASH Candidate, LPCN 1144, in Expanded Target Population

July 22, 2019

Lipocine Seeks Injunction Against the Marketing of Clarus Therapeutics' JATENZO® for Testosterone Replacement Therapy

April 2, 2019

← Newer news releases

Decks

The 5 newest of 153 decks. Every deck is listed under its year.